Serum levels of acylcarnitines are altered in prediabetic conditions

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Mai, Manuel ^a   Tönjes, Anke ^a   Kovacs, Peter ^a   Stumvoll, Michael ^a   Fiedler, Georg Martin ^b   Leichtle, Alexander Benedikt ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; ACYLCARNITINE; CARNITINE; DECANOYLCARNITINE; DECENOYLCARNITINE; HEXANOYLCARNITINE; HYDROXYBUTYRYLCARNITINE; HYDROXYHEXADECANOYLCARNITINE; HYDROXYTETRADECANOYLCARNITINE; LAUROYLCARNITINE; MALONYLCARNITINE; OCTADECENOYLCARNITINE; OCTANOYLCARNITINE; OCTENOYLCARNITINE; PROPIONYLCARNITINE; TETRADECADIENYLCARNITINE; TETRADECENOYLCARNITINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; IMPAIRED FASTING GLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST;

ADULT; AGED; BLOOD GLUCOSE; BODY COMPOSITION; CARNITINE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; PREDIABETIC STATE;

EID: 84892686032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082459     Document Type: Article

References (32)

1. Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (9467): 1333-1346.
2. Savage DB, Petersen KF, Shulman GI (2007) Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87 (2): 507-520.
3. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM (2002) Relationship between obesity, insulin resistance, and coronary heart disease risk. J. Am. Coll. Cardiol. 40 (5): 937-943.
4. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, et al. (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7 (1): 45-56.
5. Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51 (10): 2944-2950.
6. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, et al. (2010) Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18 (9): 1695-1700.
7. McGarry JD, Brown NF (1997) The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244 (1): 1-14.
8. Indiveri C, Iacobazzi V, Tonazzi A, Giangregorio N, Infantino V, et al. (2011) The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology. Mol. Aspects Med. 32(4-6): 223-233.
9. Koves TR, Li P, An J, Akimoto T, Slentz D, et al. (2005) Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J. Biol. Chem. 280 (39): 33588-33598.
10. van Hove JL, Zhang W, Kahler SG, Roe CR, Chen YT, et al. (1993) Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood. Am. J. Hum. Genet. 52 (5): 958-966.
11. Vigerust NF, Bohov P, Bjørndal B, Seifert R, Nygård O, et al. (2012) Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. Fertil. Steril. 98 (6): 1620-1626.e1.
12. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, et al. (2009) Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J. Nutr. 139 (6): 1073-1081.
13. Ha CY, Kim JY, Paik JK, Kim OY, Paik Y, et al. (2012) The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin. Endocrinol.(Oxf) 76 (5): 674-682.
14. Tai ES, Tan MLS, Stevens RD, Low YL, Muehlbauer MJ, et al. (2010) Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 53 (4): 757-767.
15. Huffman KM, Shah SH, Stevens RD, Bain JR, Muehlbauer M, et al. (2009) Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 32 (9): 1678-1683.
16. Tönjes A, Koriath M, Schleinitz D, Dietrich K, Böttcher Y, et al. (2009) Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs. Hum. Mol. Genet 18 (23): 4662-4668.
17. Tönjes A, Zeggini E, Kovacs P, Böttcher Y, Schleinitz D, et al. (2010) Association of FTO variants with BMI and fat mass in the self-contained population of Sorbs in Germany. Eur. J. Hum. Genet 18(1): 104-110.
18. (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36 Suppl 1: S67-74.
19. Vernez L, Hopfgartner G, Wenk M, Krähenbühl S (2003) Determination of carnitine and acylcarnitines in urine by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. J Chromatogr A 984 (2): 203-213.
20. Unwin N, Shaw J, Zimmet P, Alberti KGMM (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet. Med 19 (9): 708-723.
21. Faerch K, Borch-Johnsen K, Holst JJ, Vaag A (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes. Diabetologia 52 (9): 1714-1723.
22. Zhao X, Peter A, Fritsche J, Elcnerova M, Fritsche A, et al. (2009) Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at. Am. J. Physiol. Endocrinol. Metab. 296(2): E384-93.
23. Costa CC, Almeida IT de, Jakobs C, Poll-The BT, Duran M (1999) Dynamic changes of plasma acylcarnitine levels induced by fasting and sunflower oil challenge test in children. Pediatr. Res. 46 (4): 440-444.
24. Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, Defronzo RA (2008) Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetol 45 (3): 147-150.
25. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, et al. (2012) Novel biomarkers for pre-diabetes identified by metabolomics. Mol. Syst. Biol 8: 615.
26. Boden G, Shulman GI (2002) Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur. J. Clin. Invest. 32 Suppl 3: 14-23.
27. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, et al. (2010) Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE 5 (12): e15234.
28. Jourdan C, Petersen A, Gieger C, Döring A, Illig T, et al. (2012) Body fat free mass is associated with the serum metabolite profile in a population-based study. PLoS ONE 7 (6): e40009.
29. Rodríguez-Gutiérrez R, Lavalle-González FJ, Martínez-Garza LE, Landeros-Olvera E, López-Alvarenga JC, et al. (2012) Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study. J Int Soc Sports Nutr 9 (1): 22.
30. Lehmann R, Zhao X, Weigert C, Simon P, Fehrenbach E, et al. (2010) Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation. PLoS ONE 5 (7): e11519.
31. Lum H, Sloane R, Huffman KM, Kraus VB, Thompson DK, et al. (2011) Plasma acylcarnitines are associated with physical performance in elderly men. J. Gerontol. A Biol. Sci. Med. Sci. 66 (5): 548-553.
32. Wolf M, Chen S, Zhao X, Scheler M, Irmler M, et al. (2013) Production and release of acylcarnitines by primary myotubes reflect the differences in fasting fat oxidation of the donors. J. Clin. Endocrinol. Metab. 98(6): E1137-42.